Cargando…

Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers

Prostate cancer is the second leading cause of noncutaneous cancer-related deaths in American men. Androgen deprivation therapy (ADT), radical prostatectomy, and radiotherapy remain the primary treatment for patients with early-stage prostate cancer (castration-sensitive prostate cancer). Following...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitra Ghosh, Taraswi, Mazumder, Suman, Davis, Joshua, Yadav, Jyoti, Akinpelu, Ayuba, Alnaim, Ahmed, Kumar, Harish, Waliagha, Razan, Church Bird, Allison E., Rais-Bahrami, Soroush, Bird, R. Curtis, Mistriotis, Panagiotis, Mishra, Amarjit, Yates, Clayton C., Mitra, Amit K., Arnold, Robert D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355222/ https://www.ncbi.nlm.nih.gov/pubmed/37476073 http://dx.doi.org/10.1158/2767-9764.CRC-22-0427

Ejemplares similares

Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer
por: Mitra Ghosh, Taraswi, et al.
Publicado: (2021)

Extended Exposure Topotecan Significantly Improves Long-Term Drug Sensitivity by Decreasing Malignant Cell Heterogeneity and by Preventing Epithelial–Mesenchymal Transition
por: Davis, Joshua T., et al.
Publicado: (2023)

Integrating Pharmacogenomics Data-Driven Computational Drug Prediction with Single-Cell RNAseq to Demonstrate the Efficacy of a NAMPT Inhibitor against Aggressive, Taxane-Resistant, and Stem-like Cells in Lethal Prostate Cancer
por: Mazumder, Suman, et al.
Publicado: (2022)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids
por: Jyoti, Amar, et al.
Publicado: (2015)

Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence
por: Taschner-Mandl, Sabine, et al.
Publicado: (2015)

Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models
por: Hackl, Christina, et al.
Publicado: (2013)

Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALK(F1174L) Drug-Resistant Neuroblastoma Preclinical Models()
por: Zhang, Libo, et al.
Publicado: (2017)

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer
por: Di Desidero, Teresa, et al.
Publicado: (2015)

Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer
por: Kubota, Hiroki, et al.
Publicado: (2017)

Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial
por: Manji, Arif, et al.
Publicado: (2022)

A Pilot Study of Extended Adjuvant Therapy with Metronomic Docetaxel for Patients with Operable Triple-Negative Breast Cancer
por: Abdelmaksoud, Bader A, et al.
Publicado: (2020)

Commentary: Periocular topotecan for retinoblastoma
por: Sharma, Minal, et al.
Publicado: (2018)

Irg1/itaconate metabolic pathway is a crucial determinant of dendritic cells immune-priming function and contributes to resolute allergen-induced airway inflammation
por: Jaiswal, Anil Kumar, et al.
Publicado: (2021)

Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

Downregulation of YAP Activity Restricts P53 Hyperactivation to Promote Cell Survival in Confinement
por: Hemmati, Farnaz, et al.
Publicado: (2023)

Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma
por: Blanchette, P., et al.
Publicado: (2012)

Periocular topotecan for vitreous seeds in retinoblastoma
por: Sthapit, Purnima R, et al.
Publicado: (2018)

Personalized prostate cancer care
por: Rais-Bahrami, Soroush, et al.
Publicado: (2018)

Fluciclovine positron emission tomography in the setting of biochemical recurrence following local therapy of prostate cancer
por: Glaser, Zachary A., et al.
Publicado: (2018)

Metronomics for thymic carcinoma
por: del Toro, Jacobo Muñoz, et al.
Publicado: (2014)

Upper tract urologic LaparoEndoscopic Single-Site surgery
por: Rais-Bahrami, Soroush, et al.
Publicado: (2012)

Optimization of liposomal topotecan for use in treating neuroblastoma
por: Chernov, Lina, et al.
Publicado: (2017)

Role of molecular imaging in the detection of localized prostate cancer
por: Galgano, Samuel J., et al.
Publicado: (2022)

Metronomic Treatment with Low-Dose Trofosfamide Leads to a Long-Term Remission in a Patient with Docetaxel-Refractory Advanced Metastatic Prostate Cancer
por: Greiner, Jochen, et al.
Publicado: (2010)

Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2017)

Development and Validation of an HPLC Method for Analysis of Topotecan in Human Cerebrospinal Fluid and Its Application in Elimination Evaluation of Topotecan after Intraventricular Injection
por: Yoshikawa, Naoki, et al.
Publicado: (2021)

The Lipophilic Purine Nucleoside—Tdp1 Inhibitor—Enhances DNA Damage Induced by Topotecan In Vitro and Potentiates the Antitumor Effect of Topotecan In Vivo
por: Chernyshova, Irina A., et al.
Publicado: (2022)

Metronomics: Intrinsic Anakoinosis Modulator?
por: Nicolas, André, et al.
Publicado: (2018)

Metronomic Chemotherapy in Prostate Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2022)

Oral topotecan: bioavailability and effect of food co-administration
por: Herben, V M M, et al.
Publicado: (1999)

A phase I and pharmacokinetic study of intraperitoneal topotecan
por: Hofstra, L S, et al.
Publicado: (2001)

Topotecan in the treatment of relapsed small cell lung cancer
por: Quoix, Elisabeth
Publicado: (2008)

Carboplatin +/− Topotecan Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma
por: Francis, Jasmine H., et al.
Publicado: (2013)

Adverse drug reaction after intravitreal injection of topotecan
por: Narang, Subina, et al.
Publicado: (2020)

Multiparametric MRI in the PSA Screening Era
por: George, Arvin K., et al.
Publicado: (2014)

Integration of magnetic resonance imaging into prostate cancer nomograms
por: Brinkley, Garrett J., et al.
Publicado: (2022)

Head and neck cancer: metronomic chemotherapy
por: De Felice, Francesca, et al.
Publicado: (2015)

A review of topotecan in combination chemotherapy for advanced cervical cancer
por: Robati, Minoo, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_2mbvoo4vuefvp3b5ud1akfa5ak